AU6158501A - Compositions and methods for achieving immune suppression - Google Patents

Compositions and methods for achieving immune suppression

Info

Publication number
AU6158501A
AU6158501A AU6158501A AU6158501A AU6158501A AU 6158501 A AU6158501 A AU 6158501A AU 6158501 A AU6158501 A AU 6158501A AU 6158501 A AU6158501 A AU 6158501A AU 6158501 A AU6158501 A AU 6158501A
Authority
AU
Australia
Prior art keywords
compositions
methods
immune suppression
achieving immune
achieving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6158501A
Other languages
English (en)
Inventor
Terry B Strom
Wlodzimierz Maslinski
Xin Xiao Zheng
Yon Su Kim
Sylvie Ferrari Lacraz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU6158501A publication Critical patent/AU6158501A/xx
Priority to AU2006246489A priority Critical patent/AU2006246489A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
AU6158501A 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression Pending AU6158501A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006246489A AU2006246489A1 (en) 2000-05-12 2006-11-30 Compositions and methods for achieving immune suppression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20380100P 2000-05-12 2000-05-12
PCT/US2001/015578 WO2001087330A2 (en) 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression

Publications (1)

Publication Number Publication Date
AU6158501A true AU6158501A (en) 2001-11-26

Family

ID=22755375

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6158501A Pending AU6158501A (en) 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression
AU2001261585A Ceased AU2001261585B2 (en) 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001261585A Ceased AU2001261585B2 (en) 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression

Country Status (9)

Country Link
US (2) US6797263B2 (enExample)
EP (1) EP1284747A2 (enExample)
JP (1) JP2003533488A (enExample)
CN (1) CN1441675A (enExample)
AU (2) AU6158501A (enExample)
BR (1) BR0110779A (enExample)
CA (1) CA2408691A1 (enExample)
RU (1) RU2270691C2 (enExample)
WO (1) WO2001087330A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2004035787A2 (de) * 2002-10-14 2004-04-29 F. Hoffmann-La Roche Ag Transplantierbare zelle mit immunmodulator
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP1756155A2 (en) * 2004-04-14 2007-02-28 F.Hoffmann-La Roche Ag PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF
US7645575B2 (en) * 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
JP2008539765A (ja) * 2005-05-13 2008-11-20 ユニバーシティー オブ マイアミ 移植片拒絶反応および自己免疫疾患における、同種異系抗原または自己抗原に対する細胞応答の分子精査
PL1901773T3 (pl) * 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
WO2008021431A2 (en) 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CA2690825C (en) * 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
SI2665486T1 (sl) 2011-01-18 2020-07-31 Bioniz, Llc Sestavki za moduliranje aktivnosti gama-C-citokina
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP3160498B1 (en) 2014-06-30 2021-10-06 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
WO2018075989A1 (en) 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
CN107474143B (zh) * 2017-09-13 2020-08-11 深圳市因诺赛生物科技有限公司 (Anti-CD40 mAb)-CTLA4融合蛋白及其用途
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
EP4619421A2 (en) * 2023-05-01 2025-09-24 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Mutant interleukin 15 expressing immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
GB9207732D0 (en) 1992-04-06 1992-05-27 Isis Innovation Wound repair
KR0170037B1 (ko) 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
JPH08510719A (ja) 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
EP0721346B1 (en) 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
CN1137726C (zh) 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
CA2186747C (en) 1994-04-06 2009-01-27 Kenneth H. Grabstein Interleukin-15
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6265556B1 (en) 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6132978A (en) 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
JP2000503659A (ja) 1996-01-16 2000-03-28 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティー オブ ニューヨーク 自己抗体の沈着以外の開始点を有する炎症性腎疾患を処置するためのｔ―ｂａｍ（ｃｄ４０―ｌ）技術の治療的適用
JP4751493B2 (ja) 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
IL127884A0 (en) 1996-07-08 1999-10-28 Univ Columbia Agents for inhibiting activation of cells bearing C40 on the cell surface selection and use thereof
DE19823351A1 (de) 1997-05-16 1998-12-10 Krause Hans Mittel zur Verhinderung der Zellapoptose bei Krankheiten
HUP0003392A3 (en) 1997-05-17 2002-09-30 Biogen Idec Ma Inc Cambridge Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
AU748533B2 (en) 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
IL133305A0 (en) 1997-06-20 2001-04-30 Biogen Inc Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome
AU8266798A (en) 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
US6797263B2 (en) 2004-09-28
CA2408691A1 (en) 2001-11-22
US20020128436A1 (en) 2002-09-12
JP2003533488A (ja) 2003-11-11
EP1284747A2 (en) 2003-02-26
WO2001087330A2 (en) 2001-11-22
AU2001261585C1 (en) 2001-11-26
WO2001087330A3 (en) 2002-05-30
AU2001261585B2 (en) 2006-08-31
BR0110779A (pt) 2005-01-11
CN1441675A (zh) 2003-09-10
RU2270691C2 (ru) 2006-02-27
US20040219148A1 (en) 2004-11-04
US7347995B2 (en) 2008-03-25

Similar Documents

Publication Publication Date Title
AU6158501A (en) Compositions and methods for achieving immune suppression
AU2002357119A8 (en) Mitocidal compositions and methods
GB2371193B (en) Noise suppressor and noise suppressing method
AU4570901A (en) Biocidal methods and compositions
EP1176948A4 (en) COMPOSITIONS AND METHODS
EP1202941A4 (en) PLASTER COMPOSITIONS AND RELATED PROCEDURES
GB9924351D0 (en) Immunomodulation methods and compositions
IL154756A0 (en) Methods and compositions for promoting the maturation of monocytes
AU2002357748A8 (en) Osteopontin-related compositions and methods
GB0019651D0 (en) Compositions
AU7474100A (en) Methods and compositions for reducing immune response
ZA200401211B (en) Antigenic compositions
AU2002366809A8 (en) Syn3 compositions and methods
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2001253481A1 (en) Methods and compositions for eleciting an immune response
GB0004518D0 (en) Compositions
AUPQ755300A0 (en) Immune potentiating compositions
AU2002338571A1 (en) Compositions and methods for suppressing immune responses
AU1182402A (en) Methods and compositions for enhancing angiogenesis
AU4251101A (en) Synergistic herbicidal methods and compositions
GB2378135B (en) Compositions derived from modiolus modiolus and methods for making and using same
EP1264600A4 (en) IMMUNITY-BUILDING COMPOSITION AND USE OF SUCH COMPOSITIONS
HK1054187A (en) Compositions and methods for achieving immune suppression
AU2002359869A8 (en) Pak5-related compositions and methods